ROUSSET, France, September 23 /PRNewswire/ --

- The First Secure System-on-Chip Awarded Common Criteria EAL4+ Certification

Atmel(R) Corporation (Nasdaq: ATML) is proud to announce that the AT91S0100 and its derivatives have been granted Common Criteria certification EAL4+. This vulnerability assessment corresponds to today's highest proven resistance against any security attack (AVA_VLA4). The AT91SO family is compliant with EMV and PCI PED standards.

FLORHAM PARK, New Jersey, September 23 /PRNewswire/ --

Global Crossing (Nasdaq: GLBC) today announced the appointment of former Lucent Technologies CFO and current senior Alcatel-Lucent executive John Kritzmacher to the role of executive vice president and chief financial officer.

"We are pleased to welcome John to Global Crossing," said John Legere, Global Crossing's chief executive officer. "John's unique combination of financial and telecommunications expertise, global perspective and experience in dynamic organizations brings real value for our customers, shareholders and employees."

LONDON, September 23 /PRNewswire/ -- telent, a leading provider of technology services, today announced that it has acquired Premises Networks Management plc, a specialist provider of telecommunications system integration services that operates predominantly in the UK.

The acquisition is in line with telent's strategy to grow its presence and service offering in the telecommunications sector, and strengthens its presence in the medium- to large enterprise market.

LONDON, September 23 /PRNewswire/ -- FIS Software, a leading global provider of package-based software solutions for life and pensions companies, is delighted to announce the successful integration of Bright Grey's ground breaking new expert underwriting capability into ALIS.

TEL AVIV, Israel, September 23 /PRNewswire/ -- InspireMD, Ltd. announced today the enrollment of the first 3 patients in its study of MGuard(TM) coronary stent in acute myocardial infarction. The GUARD Study (MGuard(TM) in Acute Myocardial Infarction Study) is designed to evaluate the safety and efficacy of MGuard(TM) in patients suffering from ST-segment elevation myocardial infarction. The first 3 patients were implanted successfully with the MGuard(TM) Coronary Stent, in the Jagiellonian University Clinic, in Krakow, Poland.

MAIDENHEAD, England, September 23 /PRNewswire/ --

- Data Represents More than 800 Patient Years of Experience

Wyeth today announced study results from last week's 15th Paediatric Rheumatology European Congress (PRES) in London which highlight the safety record of etanercept (ENBREL(R)) as a continuous therapy in children and adolescents with juvenile idiopathic arthritis (JIA).(1)